Equity Details
Price & Market Data
Price: $4.15
Daily Change: +$0.41 / 9.88%
Daily Range: $3.68 - $4.43
Market Cap: $337,722,016
Daily Volume: 9,625,041
Performance Metrics
1 Week: 42.51%
1 Month: 140.6%
3 Months: -47.56%
6 Months: -50.78%
1 Year: -47.96%
YTD: -57.92%
About Replimune Group, Inc. (REPL)
Financial overview of Replimune Group, Inc. (REPL). Current price: 4.15, daily change: +$0.41 / 9.88%. Market cap: 337,722,016. Performance YTD, 1-week, 1-month.
Company Details
Employees: 479
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.